Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04554914 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
A Phase 2 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders, sponsored by Pierre Fabre Medicament.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT04554914 is a Phase 2 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders that is actively recruiting participants, run by Pierre Fabre Medicament. The registered enrollment target is 190 participants, above the 173-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04554914, a Phase 2 study of Stem Cell Transplant Complications and Lymphoproliferative Disorders, is actively recruiting participants, sponsored by Pierre Fabre Medicament.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
Conditions Studied
Interventions
- BIOLOGICAL Tabelecleucel
Study Locations (20)
California
- University of California Los Angeles (UCLA) (Adults and Pediatrics) - Los Angeles
- Children's Hospital of Orange County (Pediatrics [up to 25 years old]) - Orange
- Lucile Packard Children's Hospital Stanford (Pediatrics only) - Palo Alto
- University of California Davis Comprehensive Cancer Center (Adults and Pediatrics) - Sacramento
New York
- Columbia University Irving Medical Center (Adults only) - New York
- Memorial Sloan-Kettering Cancer Center (Adults and Pediatrics) - New York
- The Children's Hospital at Montefiore (Adults and Pediatrics) - The Bronx
Florida
- Sylvester Comprehensive Cancer Center/ University of Miami - Miami
- Moffit Cancer Center (Adults only) - Tampa
Georgia
- Children's Healthcare of Atlanta (Pediatrics only [up to 25 years old]) - Atlanta
- Emory University/Winship Cancer Institute (Adults [>= 16 years]) - Atlanta
Ohio
- Cleveland Clinic Taussig Cancer Center (Adults and Pediatrics) - Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute (Adults only) - Columbus
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago (Pediatrics only) - Chicago
Maryland
- University of Maryland Medical Center (Adults only) - Baltimore
Massachusetts
- Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04554914
The ClinicalTrials.gov registry entry for NCT04554914 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 173-participant average among 15 other Stem Cell Transplant Complications trials with a reported enrollment target (10% higher). The listed sponsor is Pierre Fabre Medicament, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Stem Cell Transplant Complications appearing as the primary indexed condition, and to 1 intervention - of which Tabelecleucel is the first listed.
NCT04554914 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT04554914 about?
NCT04554914 is a clinical study titled "A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases". The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
What is the current status of trial NCT04554914?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2021-07-14. Estimated completion is 2028-05.
What conditions does trial NCT04554914 study?
This clinical trial studies the following conditions: Stem Cell Transplant Complications, Lymphoproliferative Disorders, Solid Organ Transplant Complications, Allogeneic Hematopoietic Cell Transplant, Epstein-Barr Virus (EBV)-Associated Diseases.
What interventions are being tested in trial NCT04554914?
The interventions under investigation include: Tabelecleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT04554914?
This trial is sponsored by Pierre Fabre Medicament, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04554914 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stem Cell Transplant Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
COMPLETED · Phase 2
-
A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients
COMPLETED · Phase 2
-
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
RECRUITING · Phase 3
-
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
RECRUITING
Explore more on PlainTrial
Stem Cell Transplant Complications
All registered trials for this condition
Lymphoproliferative Disorders
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.